This Article Full Text Full Text (PDF) All Versions of this Article: 36/9/1904    most recent 01.STR.0000178543.19433.20v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ainsworth, C. D. Articles by Spence, J. D. Search for Related Content PubMed PubMed Citation Articles by Ainsworth, C. D. Articles by Spence, J. D. Related Collections Imaging Other diagnostic testing Doppler ultrasound, Transcranial Doppler etc.

(Stroke. 2005;36:1904.)
© 2005 American Heart Association, Inc.

Original Contributions

3D Ultrasound Measurement of Change in Carotid Plaque Volume

A Tool for Rapid Evaluation of New Therapies

Craig D. Ainsworth, MD; Christopher C. Blake, MSc; Arturo Tamayo, MD; Vadim Beletsky, MD; Aaron Fenster, PhD J. David Spence, MD

From the Stroke Prevention and Atherosclerosis Research Centre (C.D.A., A.T., V.B., J.D.S.) and Imaging Research Laboratories (C.C.B., V.B., A.F., J.D.S.), Robarts Research Institute, London, Canada.

Reprint requests to Professor David Spence, Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, 1400 Western Rd, London, ON, Canada N6G 2V2. E-mail dspence{at}robarts.ca

Background and Purpose— New therapies are being developed that are antiatherosclerotic but that lack intermediate end points, such as changes in plasma lipids, which can be measured to test efficacy. To study such treatments, it will be necessary to directly measure changes in atherosclerosis. The study was designed to determine sample sizes needed to detect effects of treatment using 3D ultrasound (US) measurement of carotid plaque.

Methods— In 38 patients with carotid stenosis >60%, age±SD 69.42±7.87 years, 15 female, randomly assigned in a double-blind fashion to 80 mg atorvastatin daily (n=17) versus placebo (n=21), we measured 3D plaque volume at baseline and after 3 months by disc segmentation of voxels representing carotid artery plaque, after 3D reconstruction of parallel transverse duplex US scans into volumetric 3D data sets.

Results— There were no significant differences in baseline risk factors. The rate of progression was 16.81±74.10 mm³ in patients taking placebo versus regression of –90.25±85.12 mm³ in patients taking atorvastatin (P<0.0001)

Conclusions— 3D plaque volume measurement can show large effects of therapy on atherosclerosis in 3 months in sample sizes of 20 patients per group. Sample sizes of 22 per group would be sufficient to show an effect size of 25% that of atorvastatin in 6 months. This technology promises to be very useful in evaluation of new therapies.

Key Words: atherosclerosis • carotid artery plaque • ultrasonography

This article has been cited by other articles:

				J. D. Spence Is Carotid Intima-Media Thickness a Reliable Clinical Predictor? Mayo Clin. Proc., November 1, 2008; 83(11): 1299 - 1300. [Full Text] [PDF]

				M. Egger, A. Krasinski, B. K. Rutt, A. Fenster, and G. Parraga Comparison of B-Mode Ultrasound, 3-Dimensional Ultrasound, and Magnetic Resonance Imaging Measurements of Carotid Atherosclerosis J. Ultrasound Med., September 1, 2008; 27(9): 1321 - 1334. [Abstract] [Full Text] [PDF]

				J. R. Crouse III Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art J. Lipid Res., August 1, 2006; 47(8): 1677 - 1699. [Abstract] [Full Text] [PDF]